Search

Your search keyword '"Van der Heijden, M."' showing total 643 results
Start Over Author "Van der Heijden, M."
643 results on '"Van der Heijden, M."'

1. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

Author

Rosenberg, J, Galsky, M, Powles, T, Petrylak, D, Bellmunt, J, Loriot, Y, Necchi, A, Hoffman-Censits, J, Perez-Gracia, J, van der Heijden, M, Dreicer, R, Durán, I, Castellano, D, Drakaki, Alexandra, Retz, M, Sridhar, S, Grivas, P, Yu, E, ODonnell, P, Burris, H, Mariathasan, S, Shi, Y, Goluboff, E, and Bajorin, D

Subjects
PD-L1-high, checkpoint inhibitor, cisplatin-ineligible, long-term survival, metastatic urothelial carcinoma, platinum-refractory, Humans, Antibodies, Monoclonal, Humanized, Male, Female, Aged, Middle Aged, Aged, 80 and over, Carcinoma, Transitional Cell, Urologic Neoplasms, Adult, B7-H1 Antigen, Treatment Outcome
Abstract

BACKGROUND: The IMvigor210 trial demonstrated clinical benefit and manageable toxicity with atezolizumab monotherapy [anti-programmed death-ligand 1 (PD-L1)] in patients with metastatic urothelial carcinoma (UC) in primary analyses. Final efficacy and safety results after long-term follow-up are reported. PATIENTS AND METHODS: This phase II single-arm trial of atezolizumab monotherapy in patients with advanced UC included two cohorts: untreated patients ineligible for cisplatin-based chemotherapy (cohort 1; n = 119) and those previously treated with platinum-based chemotherapy (cohort 2; n = 310). Atezolizumab was administered i.v. (1200 mg every 21 days) until progression or unacceptable toxicity. Primary endpoints were independent review facility-assessed confirmed objective response rate (ORR) per RECIST 1.1 in cohort 1 and independent review facility-assessed ORR per RECIST 1.1 and investigator-assessed modified (m)RECIST in cohort 2. Overall survival (OS), efficacy by PD-L1 status, and safety were also assessed. RESULTS: At data cut-off (1 June 2023), the median survival follow-up was 96.4 months (range, 0.2-103.4 months) in cohort 1 and 46.2 months [0.2 (censored)-54.9 months] in cohort 2. In cohort 1, the ORR [95% confidence interval (CI)] was 23.5% (16.2% to 32.2%) in all patients and 28.1% (13.8% to 46.8%) in the PD-L1 tumor-infiltrating immune cell (IC)2/3 subgroup. Median OS (95% CI) was 16.3 months (10.4-24.5 months) overall and 12.3 months (6.0-49.8 months) in the PD-L1 IC2/3 subgroup. In cohort 2, the ORR (95% CI) was 16.5% (12.5% to 21.1%) per RECIST 1.1 and 19.7% (95% CI 15.4% to 24.6%) per mRECIST in all patients and 27.0% (18.6% to 36.8%) and 28.0% (19.5% to 37.9%), respectively, in the PD-L1 IC2/3 subgroup. Median OS (95% CI) was 7.9 months (6.7-9.3 months) in all patients and 11.9 months (9.0-22.8 months) in the IC2/3 subgroup. Treatment-related grade 3/4 adverse events occurred in 21.8% (cohort 1) and 18.7% (cohort 2); one treatment-related death occurred in cohort 1. CONCLUSIONS: With long-term follow-up, atezolizumab monotherapy demonstrated clinically meaningful efficacy with durable responses in a subset of patients with metastatic UC; there were no new safety signals.

Published
2024

4. Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)

Author

Powles, T., primary, Grande, E., additional, Van Der Heijden, M., additional, Necchi, A., additional, Iyer, G., additional, Drakaki, A., additional, Loriot, Y., additional, Sokolowski, K., additional, Zhang, W., additional, and Galsky, M., additional

Published
2024
Full Text
View/download PDF

6. Pelvic Floor Rehabilitation After Rectal Cancer Surgery: A Multicenter Randomized Clinical Trial (FORCE Trial)

Author

van der Heijden, J. A. G., Kalkdijk-Dijkstra, A. J., Pierie, J. P. E. N., van Westreenen, H. L., Broens, P. M. A., Klarenbeek, B. R., de Wilt, JHW, Stommel, MWJ, Bremers, AJA, Rosman, C, de Reuver, PR, Bouwense, SAW, van der Kolk, BM, Garms, LM, Meerten-van den Belt, K, Olde Hartman-Hofste, MRM, Peters, JWM, Olsder, L, Huizing, I, Trzpis, M, Furnee, EJB, Havenga, K, Hemmer, PHJ, van Etten, B, Koop, A, van der Heide, L, Kamphuis, D, Koopal, SA, Hoff, C, Eker, H, Junte, HHM, Schoenaker, IJH, Quaedackers, S, Bos, MJ, Gardien, H, van Sprundel, TC, de Vries, PD, Ashruf, JF, Geurts, L, Nielen, I, Pfeil, J, van Ark, M, Polle, SW, Hansson, B, Polat, F, de Vries, H, ten Berge-Groen, E, Talsma, AK, Bosker, R, Veurink, E, Papa, M, Maaskant-Braat, AJG, van den Broek, FJC, Leclercq, WKG, Slooter, GD, Caers, F, Boeijen, M, van den Broek, R, van Schaik, K, Wasowicz-Kemps, DK, Langenhoff, BS, van den Bogaard, MJ, van der Sluis, J, Arisz, D, Bruinsma, S, Hess, DA, Mulder, EJ, Wiering, B, Kok, S, Woltering, J, Raap-van Sleuwen, B, Schoonderwoerd, L, Hendriks, D, van den Elzen, N, van de Laak, I, Valk, M, van der Meij, W, van Wely, BJ, van Hoogstraten, MJ, van der Sluis, M, Paulusma, I, Mollers, MJW, Looijen, R, van der Mijle, HCJ, Pereboom, ITA, Tijink-Callenbach, PMC, Schasfoort, RA, van der Hagen, SJ, van de Meer, W, Lubberink, M, van Haskera, M, Wit, F, Jeeninga, M, ten Hoeve, R, Slootmans, FCW, Inberg, B, de Nes, L, Toonen, D, Wilmsen, MA, Buyne, O, Ferenschild, F, de Vries, M., Adamse, C, Hettema-Beets, BL, Goudswaard, MK, van der Velde, M, Elving, DW, Arends-Smit, RE, Buiter, JR, van der itte-van Aerle, I, Jansma, K, Kooistra, L, Lohof-Venema, S, Kruijer, MR, Dijkstra, G, van der erf-Elling, MA, Kats-de Boer, V, Rinsema, AM, Haarlemmer-Lutjeboer, M, van der Vegt, A, Berends-Pors, SMH, Ponstein, AJ, Klaassen, G, Nieuwint, AM, Veninga-Jansen, M, Dries-Jansen, V, Arends, FJ, Stellingwerf-Goinga, NE, Overmars, NG, van Asma, H, Beverdam, K, Ploumen, MJAC, Tijhuis, M, Visser Duiven, AH, Former, M, Smans-Kaal, MAL, Vorsterman van Oijen-Linthorst, CMJ, Hovels-Kamp, NN, Vorsteveld, LR, Vermeulen, N, Alkemade-van Veghel, A, Steentjes, LJ, Cornelisse-Theunissen, HGM, Strijbosch, J, Sniekers, S, Oerlemans-van Oijen, JMA, Hoefnagels, HMJ, Sniekers, CJDA, Biemans, S, Bomert-Wendt, Y, van Gaal, HGM, Smulders, AHCW, Adams, W, Kappen, JM, Vermeltfoort-Jansen, AM, Zegger, MGC, Vrielink, C, Slotman, HM, Claessens, NJH, Manders-de Groot, AWM, van Beuzekom-van der Vorst, CTPG, Swinkels-Nijssen, MWC, van Oeveren, P, van Leeuwen-Nellestijn, JPF, Bleijenberg, M, Valenteyn-Hidden, JJF, van Rutten-de Groot, MG, van den van der Heijden, M, Nieuwenhuizen, Boorsma, PG, Broodman, N, Elling, ME, Bokkers-Engelen, E, Hilhorst-Droppers, GH, Mein, HJC, and Gielen, M

Published
2022
Full Text
View/download PDF

8. Validation of ACCESS: an automated tool to support self-management of COPD exacerbations

Author

Boer LM, van der Heijden M, van Kuijk NME, Lucas PJF, Vercoulen JH, Assendelft WJJ, Bischoff EW, and Schermer TR

Subjects
COPD, exacerbations, telehealth, software application, treatment advice, self-management, Diseases of the respiratory system, RC705-779
Abstract

Lonneke M Boer,1 Maarten van der Heijden,2 Nathalie ME van Kuijk,1 Peter JF Lucas,2 Jan H Vercoulen,3,4 Willem JJ Assendelft,1 Erik W Bischoff,1 Tjard R Schermer1,5 1Department of Primary and Community Care, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; 2Department of Computing Sciences, Radboud University, Nijmegen, the Netherlands; 3Department of Medical Psychology, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; 4Department of Pulmonary Diseases, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; 5Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands Background: To support patients with COPD in their self-management of symptom worsening, we developed Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS), an innovative software application that provides automated treatment advice without the interference of a health care professional. Exacerbation detection is based on 12 symptom-related yes-or-no questions and the measurement of peripheral capillary oxygen saturation (SpO2), forced expiratory volume in one second (FEV1), and body temperature. Automated treatment advice is based on a decision model built by clinical expert panel opinion and Bayesian network modeling. The current paper describes the validity of ACCESS. Methods: We performed secondary analyses on data from a 3-month prospective observational study in which patients with COPD registered respiratory symptoms daily on diary cards and measured SpO2, FEV1, and body temperature. We examined the validity of the most important treatment advice of ACCESS, ie, to contact the health care professional, against symptom- and event-based exacerbations. Results: Fifty-four patients completed 2,928 diary cards. One or more of the different pieces of ACCESS advice were provided in 71.7% of all cases. We identified 115 symptom-based exacerbations. Cross-tabulation showed a sensitivity of 97.4% (95% CI 92.0–99.3), specificity of 65.6% (95% CI 63.5–67.6), and positive and negative predictive value of 13.4% (95% CI 11.2–15.9) and 99.8% (95% CI 99.3–99.9), respectively, for ACCESS’ advice to contact a health care professional in case of an exacerbation. Conclusion: In many cases (71.7%), ACCESS gave at least one self-management advice to lower symptom burden, showing that ACCES provides self-management support for both day-to-day symptom variations and exacerbations. High sensitivity shows that if there is an exacerbation, ACCESS will advise patients to contact a health care professional. The high negative predictive value leads us to conclude that when ACCES does not provide the advice to contact a health care professional, the risk of an exacerbation is very low. Thus, ACCESS can safely be used in patients with COPD to support self-management in case of an exacerbation. Keywords: COPD, exacerbations, telehealth, software application, treatment advice, self-management, health, mobile health, automated device, diagnostic accuracy

Published
2018

14. Performance of Immersed Tunnels subjected to Settlements: Noordtunnel Case Study

Author

van der Heijden, M. (author) and van der Heijden, M. (author)

Abstract

In the next decades, Rijkswaterstaat will renovate many existing immersed tunnels so they can meet their intended lifespan in a good condition. Ongoing settlements could be a threat to the tunnel structural performance, as deformation may cause structural damage. Currently, immersed tunnels are subjected to greater and more uneven settlements than considered in the design. The issue of these ongoing settlements is mainly concentrated in the segment joints, which have typically been executed by a spigot and socket structure to prevent differential settlements. Significant deformation of the tunnel structure could result in concrete cracking, which entails the risks of structural connection loss, tunnel misalignment, and leakages (leading to durability reduction and damage to installations). This could impact the reliability of the structure over time, and consequently affect the availability of the road network. Therefore, the key objective of this research is how to assess the structural reliability and tunnel availability, and to investigate in which way the performance of existing immersed tunnel structures could be optimised given the ongoing settlements. Assessing the residual lifespan is beyond the scope, but optimising the tunnel performance during the remaining operational life is the main motivation for this research project. The research methodology consists of a parametric structural model, which determines the tunnel reliability and availability by using a Monte Carlo approach. The Noordtunnel case is used to demonstrate the research methodology, as this tunnel showed excessive settlements and a major renovation will be performed in the coming years. Additionally, the maintenance and renovation strategy for the segment joints in immersed tunnels are examined, to optimise the performance throughout the residual lifespan., Concrete Structures

Published
2023

15. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer:study protocol of the INDIBLADE trial

Author

Stockem, C. F., Mellema, J. J.J., van Rhijn, B. W.G., Boellaard, T. N., van Montfoort, M. L., Balduzzi, S., Boormans, J. L., Franckena, M., Meijer, R. P., Robbrecht, D. G.J., Suelmann, B. B.M., Schaake, E. E., van der Heijden, M. S., Stockem, C. F., Mellema, J. J.J., van Rhijn, B. W.G., Boellaard, T. N., van Montfoort, M. L., Balduzzi, S., Boormans, J. L., Franckena, M., Meijer, R. P., Robbrecht, D. G.J., Suelmann, B. B.M., Schaake, E. E., and van der Heijden, M. S.

Abstract

Introduction: Studies that assessed the efficacy of pre-operative immune checkpoint blockade (ICB) in locally advanced urothelial cancer of the bladder showed encouraging pathological complete response rates, suggesting that a bladder-sparing approach may be a viable option in a subset of patients. Chemoradiation is an alternative for radical cystectomy with similar oncological outcomes, but is still mainly used in selected patients with organ-confined tumors or patients ineligible to undergo radical cystectomy. We propose to sequentially administer ICB and chemoradiation to patients with (locally advanced) muscle-invasive bladder cancer. Methods: The INDIBLADE trial is an investigator-initiated, single-arm, multicenter phase 2 trial. Fifty patients with cT2-4aN0-2M0 urothelial bladder cancer will be treated with ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation. The primary endpoint is the bladder-intact event-free survival (BI-EFS). Events include: local or distant recurrence, salvage cystectomy, death and switch to platinum-based chemotherapy. We will also evaluate the potential of multiparametric magnetic resonance imaging of the bladder to identify non-responders, and we will assess the clearance of circulating tumor DNA as a biomarker for ICB treatment response. Discussion: This is the first trial in which the efficacy of induction combination ICB followed by chemoradiation is being evaluated to provide bladder-preservation in patients with (locally advanced) urothelial bladder cancer. Clinical Trial Registration: The INDIBLADE trial was registered on clinicaltrials.gov on January 21, 2022 (NCT05200988).

Published
2023

16. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

Author

MS Urologische Oncologie, Cancer, MS Medische Oncologie, Stockem, C. F., Mellema, J. J.J., van Rhijn, B. W.G., Boellaard, T. N., van Montfoort, M. L., Balduzzi, S., Boormans, J. L., Franckena, M., Meijer, R. P., Robbrecht, D. G.J., Suelmann, B. B.M., Schaake, E. E., van der Heijden, M. S., MS Urologische Oncologie, Cancer, MS Medische Oncologie, Stockem, C. F., Mellema, J. J.J., van Rhijn, B. W.G., Boellaard, T. N., van Montfoort, M. L., Balduzzi, S., Boormans, J. L., Franckena, M., Meijer, R. P., Robbrecht, D. G.J., Suelmann, B. B.M., Schaake, E. E., and van der Heijden, M. S.

Published
2023

20. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

Author

van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., Oldenburg, J., Chatta, G., Örön, Y., Ye, D., He, Z., Valderrama, B. P., Ku, J. H., Tomita, Y., Filian, J., and Wang, L.

Subjects
*TRANSITIONAL cell carcinoma, *NIVOLUMAB, *PROGRESSION-free survival, *SURVIVAL rate, *OVERALL survival
Abstract

BACKGROUND No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemocontlctd-therapy. METHODS In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic urothelial carcinoma either to receive intravenous nivolumab (at a dose of 360 mg) plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up to six cycles, followed by nivolumab (at a dose of 480 mg) every 4 weeks for a maximum of 2 years, or to receive gemcitabine-cisplatin alone every 3 weeks for up to six cycles. The primary outcomes were overall and progression-free survival. The objective response and safety were exploratory outcomes. RESULTS A total of608 patients underwent randomization (304 to each group). At a median follow-up of 33.6 months, overall survival was longer with nivolumab-combination therapy than with gemcitabine -cisplatin alone (hazard ratio for death, 0. 78; 95% confidence interval [CI], 0.63 to 0.96; P=0.02); the median survival was 21.7 months (95% CI, 18.6 to 26.4) as compared with 18.9 months (95% CI, 14.7 to 22.4), respectively. Progression-free survival was also longer with nivolumabcombination therapy than with gemcitabine-cisplatin alone (hazard ratio for progression or death, 0.72; 95% CI, 0.59 to 0.88; P=0.001). The median progression-free survival was Z9 months and 7.6 months, respectively. At 12 months, progression-free survival was 34.2% and 21.890, respectively. The overall objective response was 5Z6°/0 (complete response, 21.7°/0) with nivolumab-combination therapy and 43.1% (complete response, 11.8°/0) with gemcitabine-cisplatin alone. The median duration of complete response was 3Z1 months with nivolumabcombination therapy and 13.2 months with gemcitabine-cisplatin alone. Grade 3 or higher adverse events occurred in 61.8% and 51.7% of the patients, respectively. CONCLUSIONS Combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes in patients with previously untreated advanced urothetial carcinoma than gemcitabine-cisplatin alone. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 901 ClinicalTrials.gov number, NCT03036098. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.

Author

Stockem, C. F., Mellema, J. J. J., van Rhijn, B. W. G., Boellaard, T. N., van Montfoort, M. L., Balduzzi, S., Boormans, J. L., Franckena, M., Meijer, R. P., Robbrecht, D. G. J., Suelmann, B. B. M., Schaake, E. E., and van der Heijden, M. S.

Subjects
BLADDER cancer, TRANSITIONAL cell carcinoma, CIRCULATING tumor DNA, CHEMORADIOTHERAPY, NIVOLUMAB, CANCER invasiveness
Abstract

Introduction: Studies that assessed the efficacy of pre-operative immune checkpoint blockade (ICB) in locally advanced urothelial cancer of the bladder showed encouraging pathological complete response rates, suggesting that a bladder-sparing approach may be a viable option in a subset of patients. Chemoradiation is an alternative for radical cystectomy with similar oncological outcomes, but is still mainly used in selected patients with organconfined tumors or patients ineligible to undergo radical cystectomy. We propose to sequentially administer ICB and chemoradiation to patients with (locally advanced) muscle-invasive bladder cancer. Methods: The INDIBLADE trial is an investigator-initiated, single-arm, multicenter phase 2 trial. Fifty patients with cT2-4aN0-2M0 urothelial bladder cancer will be treated with ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation. The primary endpoint is the bladder-intact event-free survival (BI-EFS). Events include: local or distant recurrence, salvage cystectomy, death and switch to platinum-based chemotherapy. We will also evaluate the potential of multiparametric magnetic resonance imaging of the bladder to identify non-responders, and we will assess the clearance of circulating tumor DNA as a biomarker for ICB treatment response. Discussion: This is the first trial in which the efficacy of induction combination ICB followed by chemoradiation is being evaluated to provide bladderpreservation in patients with (locally advanced) urothelial bladder cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. 1985: eerste wereld hoeren congres in Amsterdam

Author

Pluskota, M., Lucassen, L., Heerma van Voss, L., ’t Hart, M., van der Heijden, M., Bouras, N., Lucassen, L., Heerma van Voss, L., ’t Hart, M., van der Heijden, M., and Bouras, N.

Published
2022

23. The state of the art in beyond 5G distributed massive multiple-input multiple-output communication system solutions

Author

Meyer, E., primary, Kruglov, D., additional, Krivic, M., additional, Tanveer, M., additional, Argaez-Ramirez, R., additional, Zhang, Y., additional, Briseno Ojeda, A., additional, Smirnova, K., additional, Alekseev, K., additional, Safari Mugisho, M., additional, Cimbili, B., additional, Farid, N., additional, Dang, Y., additional, Shahid, M., additional, Ensan, M., additional, Banar, J., additional, Bao, H., additional, Matters-Kammerer, M., additional, Gustavsson, U., additional, Demuynck, F., additional, Zwick, T., additional, Acar, M., additional, Fager, C., additional, van der Heijden, M., additional, Ivashina, M., additional, Caratelli, D., additional, Hasselblad, M., additional, Ulusoy, C., additional, Smolders, A.B., additional, Eriksson, K., additional, Johannson, M., additional, Maaskant, R., additional, Quay, R., additional, Floriot, D., additional, Bao, M., additional, Bronckers, L.A., additional, Fridén, J., additional, van Beurden, M.C., additional, de Hon, B.P., additional, Kolitsidas, C., additional, Blanco, D., additional, Willems, F.M.J., additional, Eriksson, T., additional, Filippi, A., additional, Ponzini, F., additional, and Johannsen, U., additional

Published
2022
Full Text
View/download PDF

26. 205. De ogen van de legioenen

Author

Heerma van Voss, L., Bouras, N., 't Hart, M., Van der Heijden, M., Lucassen, L., Groen-Vallinga, M.J., Heerma van Voss, L., Bouras, N., 't Hart, M., Van der Heijden, M., Lucassen, L., and Groen-Vallinga, M.J.

Abstract

Item does not contain fulltext

Published
2022

27. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Powles, T, Bellmunt, J, Comperat, E, De Santis, M, Huddart, R, Loriot, Y, Necchi, A, Valderrama, B P, Ravaud, A, Shariat, S F, Szabados, B, van der Heijden, M S, Gillessen, S, and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Subjects
Carcinoma, Transitional Cell, Immunoconjugates, antibody drug conjugates, Urinary bladder neoplasms, Bladder cancer, Hematology, immune checkpoint inhibitors, Oncology, Urinary Bladder Neoplasms, bladder cancer, Humans, platinum-based chemotherapy, Drug therapy, urothelial carcinoma, fibroblast growth factor receptor inhibitors, Follow-Up Studies
Abstract

Disclosure TP has received research funding from Merck Serono, Merck, Sharp & Dohme (MSD), Roche, Bristol Myers Squibb (BMS), AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and Eisai and honoraria from Merck Serono, MSD, Roche, BMS, AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and Eisai; JB has received honoraria for participation in advisory boards from Pfizer, AstraZeneca, Merck and BMS, invited speaker fees from Merck, Genentech and MSD, royalties from UpToDate, institutional research funding as principal investigator (PI) for MSD and Pfizer, research funding from Takeda and non-remunerated activities as steering committee member of the IMvigor 011 study; EC has received honoraria from Jansen for invited speaker and non-remunerated activities in an advisory role for the EAU guidelines; MDS has received honoraria for participation in advisory boards and as an invited speaker for 4D, AAA, Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, EISAI, Ferring, Immunomedics, Ipsen, Janssen, MSD, Merck Serono, Novartis, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, SeaGen and Amgen and institutional research as PI and steering committee member for Basilea, AstraZeneca, MSD, Merck, EISAI, Astellas, SeaGen, Exelixis, Ipsen, Roche, Immunomedics, Janssen and Calithera; RH has received honoraria for participation in advisory boards for Roche, Nektar, BMS, MSD and Astellas, expert testimony for National Institute of Clinical Excellence and partnership in the Cancer Centre London, institutional royalties received from Janssen, research grants from MSD and Roche, local PI for Roche, MSD, Basilea and Cancer Research UK; patient funding from Astellas and steering committee member with Cancer Research UK; YL has received honoraria for lectures, presentations, speaker’s bureau, manuscript writing or educational events from BMS, Pfizer, Merck KGaA, MSD, AstraZeneca, Roche, Jansen, Astellas, Seattle Genetics and Immunomedics and support for attending meetings and/or travel grants from BMS, Roche, AstraZeneca, MSD and Pfizer; AN has received institutional research grants from Merck, AstraZeneca, Ipsen and BMS and has undertaken personal research as a steering committee member for Roche, Janssen, Bayer, Astellas, AstraZeneca, Merck and Clovis Oncology; BPV has received honoraria for advisory boards for Pfizer, Astellas Pharma, BMS, Ipsen, EUSA Pharma, Sanofi-Aventis and Merck and has been an invited speaker for Janssen, Pfizer, BMS, Roche, Bayer, EUSA Pharma, MSD and Merck; AR has received honoraria for advisory boards for Pfizer, Merck GA, BMS, Ipsen, MSD and AstraZeneca and has been an invited speaker for Pfizer, Merck GA, BMS, Ipsen and MSD and has received institutional grants from Pfizer, Merck GA and Ipsen; SFS has received honoraria for participation in advisory boards for Astellas, Janssen, MSD, AstraZeneca, Bayer, BMS, Cepheid, Ferring Pharmaceuticals, Ipsen, Lilly, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda and UroGen; BS has received honoraria from Ellipses, Ipsen, Merck, Pfizer and Roche and has received travel and research funding from BMS, Genentech, MSD, Pfizer and Roche; MSvdH has received honoraria (paid to institute) for participation in advisory boards for BMS, Roche, Seagen, AstraZeneca, Janssen, Pfizer and MSD, stock ownership with Gilead; and institutional research funding from BMS, Roche, AstraZeneca and 4SC; SG has received personal honoraria for participation in advisory boards for Sanofi, Orion, Roche, Amgen, MSD and Aranda; other honoraria from RSI Televisione Svizzera Italiana); has been an invited speaker for ESMO, SAKK, SAMO, Orikata and CACA-GU, speaker’s bureau for Janssen Cilag; travel grant from ProteoMEdiX, institutional honoraria for advisory boards for Bayer, Janssen Cilag, Roche and AAA International including Independent Data Monitoring Committee; steering committee for Amgen, Menarini Silicon Biosystems, Astellas Pharma, Tolero Pharmaceuticals, MSD, Pfizer, Telixpharma, BMS and Orion and has received a patent, royalties and other intellectual property from Method for Biomarker WO2009138392.

Published
2022

28. 205. De ogen van de legioenen

Author

Groen-Vallinga, M.J., Heerma van Voss, L., Bouras, N., 't Hart, M., Van der Heijden, M., and Lucassen, L.

Published
2022

35. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie

Author

Loriot, Y., primary, Vuillet, M., additional, Mamtani, R., additional, Rosenberg, J., additional, Powles, T., additional, Sonpavde, G., additional, Duran, I., additional, Lee, J., additional, Matsubara, N., additional, Vulsteke, C., additional, Castellano, D., additional, Sridhar, S., additional, Pappo, H., additional, Valderram, B., additional, Gurney, H., additional, Bedke, J., additional, Van der heijden, M., additional, Hepp, Z., additional, and Petrylak, D., additional

Published
2021
Full Text
View/download PDF

42. CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer

Author

Powles, T, primary, Szabados, B, additional, Castellano, D, additional, Rodriguez-Vida, A, additional, Valderrama, B, additional, Crabb, S, additional, Van Der Heijden, M, additional, Pous, AF, additional, Prendergast, A, additional, Gravis, G, additional, Herranz, UA, additional, Sharma, S, additional, Ravauld, A, additional, Sethi, H, additional, Zimmerman, B, additional, Aleshin, A, additional, Kockx, M, additional, Banchereau, R, additional, Mariathasan, S, additional, and Assaf, ZJ, additional

Published
2020
Full Text
View/download PDF

44. PD-0543: An externally validated prognostic CT radiomics model for head and neck cancer patients

Author

Keek, S., primary, Sanduleanu, S., additional, Woodruff, H.C., additional, Wesseling, F., additional, Mattavelli, D., additional, Ravanelli, M., additional, Hoffman, T.K., additional, Scheckenbach, K., additional, Leemans, C.R., additional, De Graaf, P., additional, Terhaard, C., additional, Van de Kamer, J., additional, Van der Heijden, M., additional, Calareso, G., additional, Gazzani, E.S., additional, Licitra, L., additional, Hoebers, F., additional, Poli, T., additional, and Lambin, P., additional

Published
2020
Full Text
View/download PDF

46. Corrigendum re: 'Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens' (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))

Author

Perez-Gracia J. L., Loriot Y., Rosenberg J. E., Powles T., Necchi A., Hussain S. A., Morales-Barrera R., Retz M. M., Niegisch G., Duran I., Theodore C., Grande E., Shen X., Wang J., Nelson B., Derleth C. L., van der Heijden M. S., Perez-Gracia, J. L., Loriot, Y., Rosenberg, J. E., Powles, T., Necchi, A., Hussain, S. A., Morales-Barrera, R., Retz, M. M., Niegisch, G., Duran, I., Theodore, C., Grande, E., Shen, X., Wang, J., Nelson, B., Derleth, C. L., and van der Heijden, M. S.

Abstract

A review of potential conflicts of interest for all the authors in relation to this study revealed further items that Rafael Morales-Barrera and Enrique Grande wish to disclose. The conflicts of interest statement with full disclosures is therefore as follows. Financial disclosures: Jose Luis Perez-Gracia certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Jose Luis Perez-Gracia has received grants or funding from Roche, had consultancies with Roche, and received honoraria from Roche. Yohann Loriot has received grants from Sanofi and fees for consulting or advisory roles from Astellas, AstraZeneca, Janssen, MSD, Roche, and Sanofi. Jonathan E. Rosenberg has received grants or funding from Bristol-Myers Squibb and Roche and has had consultancies with Agensys, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, EMD-Serono, Merck, Roche, and Seattle Genetics. Thomas Powles has received grants or funding from AstraZeneca and Roche and received honoraria from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche. Andrea Necchi has received grants or funding from Amgen, AstraZeneca, and Merck & Co. Inc., had consultancies with Astellas/Seattle Genetics, AstraZeneca, Bayer, Merck & Co. Inc., Pfizer, and Roche, and received honoraria from Merck & Co. Inc., Pierre Fabre, and PeerVoice Roche. Syed A. Hussain has attended advisory board meetings with AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Pierre Fabre, and Roche and received educational grants and institutional funding from Cancer Research UK, Boehringer Ingelheim, Janssen, and Eli Lilly. Morales-Barrera has no financial disclosures. Margitta M. Retz is employed by and affiliated with Technical University Munich, Germany Klnikum rechts der Isar, Department of Urology. Günter Niegisch has received grants or funding from 4SC AG, had consultancies with Bristol-Myers Squibb, IMS Health AG, medac GmbH, and Roche Pharma AG and received honoraria from Pfizer Pharma GmbH, Pierre Fabre Pharma GmbH, and Roche Pharma AG. Ignacio Durán has received grants or funding from Roche-Genentech, had consultancies with Bristol-Myers Squibb, Merck Sharp & Dohme Corp, and Roche-Genentech, and received honoraria from Merck Sharp & Dohme Corp, Pierre Fabre, and Roche. Christine Théodore has no financial disclosures. Betty Nelson, Xiaodong Shen, and Christina L. Derleth are employed by Genentech and own Roche stock. Jingjing Wang is a consultant of Genentech. Michiel S.van der Heijden has received grants or funding from Astellas and had consultancies with Astellas, AstraZeneca, Bristol-Myers Squibb, and Roche-Genentech. Rafael Morales-Barrera has received speaker honoraria or travel support from Bayer, Roche, Astellas, Janssen-Cilag, MSD, and Sanofi-Aventis. Enrique Grande has received honoraria for advisory boards, meetings, and/or lectures from Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, and Celgene, and has received unrestricted research grants from Pfizer, AstraZeneca, MTEM/Threshold, Roche, IPSEN, and Lexicon.

Published
2019

47. Symbiotic soil fungi enhance ecosystem resilience to climate change

Author

Martinez-Garcia, Laura B, De Deyn, Gerlinde B, Pugnaire, Francisco I, Kothamasi, David, van der Heijden, M G A, Sub Plant-Microbe Interactions, Plant Microbe Interactions, Sub Plant-Microbe Interactions, and Plant Microbe Interactions

Subjects
0106 biological sciences, rainfallregimes, rainfall regimes, Nitrogen, Soil biology, Climate Change, Rain, Arbuscular mycorrhizal fungi, arbuscular mycorrhizal fungi, 01 natural sciences, Nutrient, Nutrient leaching, Mycorrhizae, Environmental Chemistry, Climate change, Ecosystem, Primary Research Article, Precipitation, Leaching (agriculture), Symbiosis, Rainfall regimes, Bodembiologie, Soil Microbiology, General Environmental Science, 2. Zero hunger, Global and Planetary Change, Ecology, fungi, Tropics, Phosphorus, 04 agricultural and veterinary sciences, Soil Biology, 15. Life on land, PE&RC, Primary Research Articles, Agronomy, 13. Climate action, Soil water, nutrient leaching, 040103 agronomy & agriculture, 0401 agriculture, forestry, and fisheries, Environmental science, Eutrophication, 010606 plant biology & botany
Abstract

Substantial amounts of nutrients are lost from soils through leaching. These losses can be environmentally damaging, causing groundwater eutrophication and also comprise an economic burden in terms of lost agricultural production. More intense precipitation events caused by climate change will likely aggravate this problem. So far it is unresolved to which extent soil biota can make ecosystems more resilient to climate change and reduce nutrient leaching losses when rainfall intensity increases. In this study, we focused on arbuscular mycorrhizal (AM) fungi, common soil fungi that form symbiotic associations with most land plants and which increase plant nutrient uptake. We hypothesized that AM fungi mitigate nutrient losses following intensive precipitation events (higher amount of precipitation and rain events frequency). To test this, we manipulated the presence of AM fungi in model grassland communities subjected to two rainfall scenarios: moderate and high rainfall intensity. The total amount of nutrients lost through leaching increased substantially with higher rainfall intensity. The presence of AM fungi reduced phosphorus losses by 50% under both rainfall scenarios and nitrogen losses by 40% under high rainfall intensity. Thus, the presence of AM fungi enhanced the nutrient interception ability of soils, and AM fungi reduced the nutrient leaching risk when rainfall intensity increases. These findings are especially relevant in areas with high rainfall intensity (e.g. such as the tropics) and for ecosystems that will experience increased rainfall due to climate change. Overall, this work demonstrates that soil biota such as AM fungi can enhance ecosystem resilience and reduce the negative impact of increased precipitation on nutrient losses. This article is protected by copyright. All rights reserved.

Published
2017

48. Colon cancer dynamics in development, progression and growt

Author

van der Heijden, M. C. S., Vermeulen, Louis, Medema, Jan Paul, Winton, Douglas J., Center of Experimental and Molecular Medicine, AGEM - Re-generation and cancer of the digestive system, AGEM - Digestive immunity, Graduate School, and CCA - Cancer biology and immunology

Subjects
neoplasms, digestive system diseases
Abstract

Colorectal cancer (CRC) remains an important cause of cancer related death worldwide. Early stage disease is often still curable but the availability of curative therapies for metastasized CRC is limited. Our aim was to gain a better understanding of the underlying growth dynamics of this disease to hopefully unravel new therapeutic avenues that will eventually improve patient outcomes. Therefore, we have investigated the fundamental growth dynamics of CRC during initiation, progression and growth, in both a qualitative as quantitative fashion. The work presented in this thesis, demonstrates that different selection dynamics underlie the multistep CRC evolution and the existence of an intimate relationship between the CRC cells and their environment.

Published
2020

50. Measurement of the $$\Gamma _{b\bar b} /\Gamma _{had} $$ branching ratio of thez by double hemisphere tagging

Author

Abreu, P., Adam, W., Adye, T., Agasi, E., Ajinenko, I., Aleksan, R., Alekseev, G. D., Allport, P. P., Almehed, S., Almeida, F. M. L., Alvsvaag, S. J., Amaldi, U., Andreazza, A., Antilogus, P., Apel, W -D., Apsimon, R. J., Arnoud, Y., Asman, B., Augustin, J -E., Augustinus, A., Baillon, P., Bambade, P., Barao, F., Barate, R., Barbiellini, G., Bardin, D. Y., Barker, G. J., Baroncelli, A., Barring, O., Barrio, J. A., Bartl, W., Bates, M. J., Battaglia, M., Baubillier, M., Baudot, J., Becks, K -H., Begalli, M., Beilliere, P., Belokopytov, Yu., Beltran, P., Benvenuti, A. C., Berggren, M., Bertrand, D., Bianchi, F., Bigi, M., Bilenky, M. S., Billoir, P., Bjarne, J., Bloch, D., Blocki, J., Blyth, S., Bocci, V., Bogolubov, P. N., Bolognese, T., Bonesini, M., Bonivento, W., Booth, P. S. L., Borisov, G., Bosio, C., Bostjancic, B., Bosworth, S., Botner, O., Bouquet, B., Bourdarios, C., Bowcock, T. J. V., Bozzo, M., Braibant, S., Branchini, P., Brand, K. D., Brenner, R. A., Briand, H., Bricman, C., Brillault, L., Brown, R. C. A., Bruckman, P., Brunet, J -M., Bugge, L., Buran, T., Buys, A., Buytaert, J. A. M. A., Caccia, M., Calvi, M., Camacho Rozas, A. J., Campion, R., Camporesi, T., Canale, V., Cankocak, K., Cao, F., Carena, F., Carrilho, P., Carroll, L., Cases, R., Caso, C., Castillo Gimenez, M. V., Cattai, A., Cavallo, F. R., Cerrito, L., Chabaud, V., Chan, A., Charpentier, Ph., Chaussard, L., Chauveau, J., Checchia, P., Chelkov, G. A., Chliapnikov, P., Chorowicz, V., Chrin, J. T. M., Cindro, V., Collins, P., Contreras, J. L., Contri, R., Cortina, E., Cosme, G., Couchot, F., Crawley, H. B., Crennell, D., Crosetti, G., Maestro, J. Cuevas, Czellar, S., Dahl-Jensen, E., Dahm, J., Dalmagne, B., Dam, M., Damgaard, G., Daubie, E., Daum, A., Dauncey, P. D., Davenport, M., Davies, J., Da Silva, W., Defoix, C., Delpierre, P., Demaria, N., De Angelis, A., De Boeck, H., De Boer, W., De Brabandere, S., De Clercq, C., De Fez Laso, M. D. M., De La Vaissiere, C., De Lotto, B., De Min, A., De Paula, L., De Saint-Jean, C., Dijkstra, H., Di Ciaccio, L., Djama, F., Dolbeau, J., Donszelmann, M., Doroba, K., Dracos, M., Drees, J., Dris, M., Dufour, Y., Dupont, F., Edsall, D., Ehret, R., Ekelof, T., Ekspong, G., Elsing, M., Engel, J -P., Ershaidat, N., Santo, M. Espirito, Fassouliotis, D., Feindt, M., Fenyuk, A., Ferrer, A., Fillippas, T. A., Firestone, A., Foeth, H., Fokitis, E., Fontanelli, F., Formenti, F., Fousset, J -L., Franek, B., Frenkiel, P., Fries, D. C., Frodesen, A. G., Fruhwirth, R., Fulda-Quenzer, F., Furstenau, H., Fuster, J., Gamba, D., Gandelman, M., Garcia, C., Garcia, J., Gaspar, C., Gasparini, U., Gavillet, Ph., Gazis, E. N., Gele, D., Gerber, J -P., Giacomelli, P., Gillespie, D., Gokieli, R., Golob, B., Golovatyuk, V. M., Gomez Y Cadenas, J. J., Gopal, G., Gorn, L., Gorski, M., Gracco, V., Grard, F., Graziani, E., Grosdidier, G., Gunnarsson, P., Guy, J., Haedinger, U., Hahn, F., Hahn, M., Hahn, S., Haider, S., Hajduk, Z., Hakansson, A., Hallgren, A., Hamacher, K., Hao, W., Harris, F. J., Hedberg, V., Henriques, R., Hernandez, J. J., Hernando, J. A., Herquet, P., Herr, H., Hessing, T. L., Higon, E., Hilke, H. J., Hill, T. S., Holmgren, S -O., Holt, P. J., Holthuizen, D., Honore, P. F., Houlden, M., Hrubec, J., Huet, K., Hultqvist, K., Ioannou, P., Iversen, P -S., Jackson, J. N., Jacobsson, R., Jalocha, P., Jarlskog, G., Jarry, P., Jean-Marie, B., Johansson, E. K., Jonker, M., Jonsson, L., Juillot, P., Kaiser, M., Kalmus, G., Kapusta, F., Karlsson, M., Karvelas, E., Katsanevas, S., Katsoufis, E. C., Keranen, R., Khomenko, B. A., Khovanski, N. N., King, B., Kjaer, N. J., Klein, H., Klovning, A., Kluit, P., Koch-Mehrin, A., Koehne, J. H., Koene, B., Kokkinias, P., Koratzinos, M., Korytov, A. V., Kostioukhine, V., Kourkoumelis, C., Kouznetsov, O., Kramer, P. H., Krammer, M., Kreuter, C., Krolikowski, J., Kronkvist, I., Krupinski, W., Kucewicz, W., Kulka, K., Kurvinen, K., Lacasta, C., Laktineh, I., Lambropoulos, C., Lamsa, J. W., Lanceri, L., Langefeld, P., Lapin, V., Last, I., Laugier, J -P., Lauhakangas, R., Leder, G., Ledroit, F., Leitner, R., Lemoigne, Y., Lemonne, J., Lenzen, G., Lepeltier, V., Lesiak, T., Levy, J. M., Lieb, E., Liko, D., Lindner, R., Lipniacka, A., Lippi, I., Loerstad, B., Lokajicek, M., Loken, J. G., Lopez-Fernandez, A., Lopez Aguera, M. A., Los, M., Loukas, D., Lozano, J. J., Lutz, P., Lyons, L., Maehlum, G., Maillard, J., Maio, A., Maltezos, A., Marco, J., Marechal, B., Margoni, M., Marin, J -C., Mariotti, C., Markou, A., Maron, T., Marti, S., Martinez-Rivero, C., Martinez-Vidal, F., Matorras, F., Matteuzzi, C., Matthiae, G., Mazzucato, M., Cubbin, M. Mc., Kay, R. Mc, Nulty, R. Mc, Medbo, J., Meroni, C., Meyer, W. T., Michelotto, M., Migliore, E., Mikulec, I., Mirabito, L., Mitaroff, W. A., Mitselmakher, G. V., Mjoernmark, U., Moa, T., Moeller, R., Moenig, K., Monge, M. R., Morettini, P., Mueller, H., Murray, W. J., Muryn, B., Myatt, G., Naraghi, F., Navarria, F. L., Negri, P., Nemecek, S., Neumann, W., Neumeister, N., Nicolaidou, R., Nielsen, B. S., Nikolaenko, V., Niss, P., Nomerotski, A., Normand, A., Obraztsov, V., Olshevski, A. G., Orava, R., Osterberg, K., Ouraou, A., Paganini, P., Paganoni, M., Pain, R., Palka, H., Papadopoulou, Th. D., Pape, L., Parodi, F., Passeri, A., Pegoraro, M., Pennanen, J., Peralta, L., Perevozchikov, V., Pernegger, H., Pernicka, M., Perrotta, A., Petridou, C., Petrolini, A., Phillips, H. T., Piana, G., Pierre, F., Pimenta, M., Plaszczynski, S., Podobrin, O., Pol, M. E., Polok, G., Poropat, P., Pozdniakov, V., Prest, M., Privitera, P., Pullia, A., Radojicic, D., Ragazzi, S., Rahmani, H., Rames, J., Ratoff, P. N., Read, A. L., Reale, M., Rebecchi, P., Redaelli, N. G., Regler, M., Reid, D., Renton, P. B., Resvanis, L. K., Richard, F., Richardson, J., Ridky, J., Rinaudo, G., Ripp, I., Romero, A., Roncagliolo, I., Ronchese, P., Ronjin, V., Roos, L., Rosenberg, E. I., Rosso, E., Roudeau, P., Rovelli, T., Ruckstuhl, W., Ruhlmann-Kleider, V., Ruiz, A., Saarikko, H., Sacquin, Y., Sajot, G., Salt, J., Sanchez, J., Sannino, M., Schael, S., Schneider, H., Schyns, M. A. E., Sciolla, G., Scuri, F., Segar, A. M., Seitz, A., Sekulin, R., Sessa, M., Seufert, R., Shellard, R. C., Siccama, I., Siegrist, P., Simonetti, S., Simonetto, F., Sisakian, A. N., Skaali, T. B., Smadja, G., Smirnov, N., Smirnova, O., Smith, G. R., Sosnowski, R., Douza-Santos, D., Spassov, T., Spiriti, E., Squarcia, S., Staeck, H., Stanescu, C., Stapnes, S., Stavitski, I., Stavropoulos, G., Stepaniak, K., Stichelbaut, F., Stocchi, A., Strauss, J., Straver, J., Strub, R., Stugu, B., Szczekowski, M., Szeptycka, M., Tabarelli, T., Tchikilev, O., Theodosiou, G. E., Thome, Z., Tilquin, A., Timmermans, J., Timofeev, V. G., Tkatchev, L. G., Todorov, T., Toet, D. Z., Tomaradze, A., Tome, B., torassa, E., Tortora, L., Transtromer, G., Treille, D., Tristram, G., Troncon, C., Tsirou, A., Tsyganov, E. N., Turluer, M -L., Tuuva, T., Tyapkin, I. A., Tyndel, M., Tzamarias, S., Ueberschaer, B., Ueberschaer, S., Ullaland, O., Uvarov, V., Valenti, G., Vallazza, E., Valls Ferrer, J. A., Vander Velde, C., Van Apeldoorn, G. W., Van Dam, P., Van Der Heijden, M., Van Doninck, W. K., Van Eldik, J., Vaz, P., Vegni, G., Ventura, L., Venus, W., Verbeure, F., Verlato, M., Vertogradov, L. S., Vilanova, D., Vincent, P., Vitale, L., Vlasov, E., Vodopyanov, A. S., Vollmer, M., Voutilainen, M., Vrba, V., Wahlen, H., Walck, C., Waldner, F., Wehr, A., Weierstall, M., Weilhammer, P., Wetherell, A. M., Wickens, J. H., Wielers, M., Wilkinson, G. R., Williams, W. S. C., Winter, M., Witek, M., Wormser, G., Woschnagg, K., Yip, K., Yushchenko, O., Zach, F., Zaitsev, A., Zalewska, A., Zalewski, P., Zavrtanik, D., Zevgolatakos, E., Zimin, N. I., Zito, M., Zontar, D., Zuberi, R., Zumerle, G., and DELPHI Collaboration

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results